Systemic Sclerosis-Specific Antibodies: Novel and Classical Biomarkers

Mehra S, Walker J, Patterson K, Fritzler MJ (2013) Autoantibodies in systemic sclerosis. Autoimmun Rev 12:340–354. https://doi.org/10.1016/j.autrev.2012.05.011

CAS  Article  PubMed  Google Scholar 

FDA-NIH Biomarker Working Group (2016) BEST (Biomarkers, EndpointS, and other Tools) resource. Food and Drug Administration (US), Silver Spring (MD). https://www.ncbi.nlm.nih.gov/books/NBK338449

Califf R (2018) Biomarker definitions and their applications. Exp Biol Med (Maywood) 243:213–221. https://doi.org/10.1177/1535370217750088

CAS  Article  Google Scholar 

Robb MA, McInnes PM, Califf RM (2016) Biomarkers and surrogate endpoints: developing common terminology and definitions. JAMA 315:1107–1108. https://doi.org/10.1001/jama.2016.2240

CAS  Article  PubMed  Google Scholar 

Nihtyanova SI, Denton CP (2010) Autoantibodies as predictive tools in systemic sclerosis. Nat Rev Rheumatol 6:112–116. https://doi.org/10.1038/nrrheum.2009.238

CAS  Article  PubMed  Google Scholar 

Heijnen IAFM, Foocharoen C, Bannert B et al (2013) Clinical significance of coexisting antitopoisomerase I and anticentromere antibodies in patients with systemic sclerosis: a EUSTAR group-based study. Clin Exp Rheumatol 31:96–102

PubMed  Google Scholar 

Patterson KA, Roberts-Thomson PJ, Lester S, Tan JA, Hakendorf P, Rischmueller M et al (2015) Interpretation of an extended autoantibody profile in a well-characterized australian systemic sclerosis (scleroderma) cohort using principal components analysis. Arthritis Rheumatol 67(12):3234–3244. https://doi.org/10.1002/art.39316

CAS  Article  PubMed  Google Scholar 

Steen VD (2005) Autoantibodies in Systemic Sclerosis. Semin Arthritis Rheum 35:35–42

CAS  PubMed  Article  Google Scholar 

Henes J, Glaeser L, Kotter I, Vogel W, Kanz L, Klein R (2017) Analysis of anti–topoisomerase I antibodies in patients with systemic sclerosis before and after autologous stem cell transplantation. Rheumatol 56:451–456

CAS  Google Scholar 

Burbelo PD, Gordon SM, Waldman M, Edison JD, Little DJ, Stitt RS et al (2019) Autoantibodies are present before the clinical diagnosis of systemic sclerosis. PLoS ONE 14:e0214202. https://doi.org/10.1371/journal.pone.0214202

CAS  Article  PubMed  PubMed Central  Google Scholar 

Raschi E, Privitera D, Bodio C, Lonati PA, Borghi MO, Ingegnoli F et al (2020) Scleroderma-specific autoantibodies embedded in immune complexes mediate endothelial damage: an early event in the pathogenesis of systemic sclerosis. Arthr Care Res 22:265. https://doi.org/10.1186/s13075-020-02360-3

CAS  Article  Google Scholar 

Raschi E, Chighizola CB, Cesana L, Privitera D, Ingegnoli F, Mastaglio F et al (2018) Immune complexes containing scleroderma-specific autoantibodies induce a profibrotic and proinflammatory phenotype in skin fibroblasts. Arthritis Res Ther 20:187. https://doi.org/10.1186/s13075-018-1689-6

CAS  Article  PubMed  PubMed Central  Google Scholar 

van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A et al (2013) 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum 65:2737–2747

PubMed  PubMed Central  Article  Google Scholar 

Satoh M, Vázquez-Del Mercado M, Chan EK (2009) Clinical interpretation of antinuclear antibody tests in systemic rheumatic diseases. Mod Rheumatol 19:219–228. https://doi.org/10.1007/s10165-009-0155-3

CAS  Article  PubMed  PubMed Central  Google Scholar 

Kuwana M, Okano Y, Pandey JP, Silver RM, Fertig N, Medsger TA Jr (2005) Enzyme linked immunosorbent assay for detection of anti-RNA polymerase III antibody: analytical accuracy and clinical associations in systemic sclerosis. Arthritis Rheum 52:2425–2432

CAS  PubMed  Article  Google Scholar 

Satoh T, Ishikawa O, Ihn H et al (2009) Clinical usefulness of anti-RNA polymerase III antibody measurement by enzyme-linked immunosorbent assay. Rheumatology 48:1570–1574

CAS  PubMed  Article  Google Scholar 

Mitri GM, Lucas M, Fertig N, Steen VD, Medsger TA Jr (2003) A comparison between anti-Th/To– and anticentromere antibody–positive systemic sclerosis patients with limited cutaneous involvement. Arthritis Rheum 48:203–209. https://doi.org/10.1002/art.10760

Article  PubMed  Google Scholar 

Reveille JD, Solomon SH (2003) Evidence-based guidelines for the use of immunologic tests: anticentromere, Scl-70, and nucleolar antibodies. Arthr Rheum 49:399–412

Article  Google Scholar 

Ceribelli A, Cavazzana I, Franceschini F, Airò P, Tincani A, Cattaneo R et al (2010) Anti-Th/To are common antinucleolar autoantibodies in Italian patients with scleroderma. J Rheumatol 37:2071–2075. https://doi.org/10.3899/jrheum.100316

CAS  Article  PubMed  Google Scholar 

Mahler M, Gascon C, Patel S, Ceribelli A, Fritzler MJ, Swart A et al (2013) Rpp25 is a major target of autoantibodies to the Th/To complex as measured by a novel chemiluminescent assay. Arthritis Res Ther 15:R50. https://doi.org/10.1186/ar4210

CAS  Article  PubMed  PubMed Central  Google Scholar 

Villalta D, Morozzi G, Tampoia M, Alpini C, Brusca I, Salgarolo V et al (2010) Antibodies to fibrillarin, PM-Scl and RNA polymerase III detected by ELISA assays in patients with systemic sclerosis. Clin Chim Acta 411:710–713

CAS  PubMed  Article  Google Scholar 

Agmon-Levin N, Damoiseaux J, Kallenberg C, Sack U, Witte T, Herold M et al (2014) International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. Ann Rheum Dis 73:17–23

CAS  PubMed  Article  Google Scholar 

Conrad K, Andrade LE, Chan EK, Mahler M, Meroni PL, Pruijn GJ et al (2016) From autoantibody research to standardized diagnostic assays in the management of human diseases - report of the 12th Dresden Symposium on Autoantibodies. Lupus 25:787–796

CAS  PubMed  Article  Google Scholar 

Meroni PL, Chan EK, Damoiseaux J, Andrade LEC, Bossuyt X, Conrad K et al (2019) Unending story of the indirect immunofluorescence assay on HEp-2 cells: old problems and new solutions? Ann Rheum Dis 78:e46

PubMed  Article  Google Scholar 

Choi HW, Kwon YJ, Park JH, Lee SY, Chun S, Won EJ et al (2020) Evaluation of a fully automated antinuclear antibody indirect immunofluorescence assay in routine use. Front Immunol 11:607541

CAS  PubMed  PubMed Central  Article  Google Scholar 

Irure-Ventura J, Rodríguez C, Vergara-Prieto E, Vargas ML, Quirant B, Jurado A et al (2021) Rare immunofluorescence patterns of autoantibodies on HEp-2 cells defined by ICAP identify different autoimmune diseases in the absence of associated specificities: a Spanish multicentre study. Rheumatology 60:3904–3912. https://doi.org/10.1093/rheumatology/keaa831

Article  PubMed  Google Scholar 

D’Aoust J, Hudson M, Tatibouet S, Wick J et al (2014) Clinical and serologic correlates of anti-PM/scl antibodies in systemic sclerosis: a multicenter study of 763 patients. Arthritis Rheum 66:1608–1615

Article  CAS  Google Scholar 

Reveille JD, Solomon DH, The ACR Ad Hoc Committee on Immunologic Testing Guidelines (2003) Evidence-based guidelines for the use of immunologic tests: anticentromere, Scl-70, and nucleolar antibodies. Arthritis Care Res 49:399–412

Article  Google Scholar 

LeRoy EC, Medsger TA Jr (2001) Criteria for the classification of early systemic sclerosis. J Rheumatol 28:1573–1576

CAS  PubMed  Google Scholar 

Koenig M, Joyal F, Fritzler MJ, Roussin A, Abrahamowicz M, Boire G et al (2008) Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud’s phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. Arthritis Rheum 58:3902–3912

PubMed  Article  Google Scholar 

Salazar GA, Assassi S, Wigley F, Hummers L, Varga J, Hinchcliff M et al (2015) Antinuclear antibody-negative systemic sclerosis. Semin Arthritis Rheum 44:680–686. https://doi.org/10.1016/j.semarthrit.2014.11.006

CAS  Article  PubMed  Google Scholar 

Weiner ES, Hildebrandt S, Senecal JL, Daniels L, Noell S, Joyal F et al (1991) Prognostic significance of anticentromere antibodies and anti–topoisomerase I antibodies in Raynaud’s disease: a prospective study. Arthritis Rheum 34:68–77

CAS  PubMed  Article  Google Scholar 

Koenig M, Dieude M, Senecal JL (2008) Predictive value of antinuclear antibodies: the lessons of systemic sclerosis autoantibodies. Autoimmun Rev 7:588–593

CAS  PubMed  Article  Google Scholar 

Earnshaw WC, Machlin PS, Bordwell BJ et al (1987) Analysis of anticentromere autoantibodies using cloned autoantigen CENP-B. Proc Natl Acad Sci USA 84:4979–4983

CAS  PubMed  PubMed Central  Article  Google Scholar 

Fritzler MJ, Rattner JB, Luft LAM et al (2011) Historical perspectives on the discovery and elucidation of autoantibodies to centromere proteins (CENP) and the emerging importance of antibodies to CENP-F. Autoimmun Rev 10:194–200

CAS  PubMed  Article  Google Scholar 

Song G, Hu C, Zhu H, Wang L, Zhang F, Li Y et al (2013) New centromere autoantigens identified in systemic sclerosis using centromere protein microarrays. J Rheumatol 40:461–468

CAS  PubMed  PubMed Central  Article  Google Scholar 

Cavazzana I, Franceschini F (2014) Centromere antibodies. In: Shoenfeld Y, Meroni PL, Gershwin ME (eds) Autoantibodies, 3rd edn. Elsevier, pp 179–184

Chapter  Google Scholar 

Caetano J, Nihtyanova SI, Harvey J, Denton CP, Ong VH (2018) Distinctive clinical phenotype of anti-centromere antibody-positive diffuse systemic sclerosis. Rheumatol Adv Pract 2:rky002

PubMed  PubMed Central  Article  Google Scholar 

Hudson M, Mahler M, Pope J, You D et al (2012) Clinical correlates of CENP-A and CENP-B antibodies in a large cohort of patients with systemic sclerosis. J Rheumatol 39:787–794

PubMed 

留言 (0)

沒有登入
gif